BioNixus helps pharmaceutical market access and HEOR teams source, generate, and analyse real-world data across the Middle East — from UAE Salama EMR datasets and Saudi NHIC aggregated records to primary chart reviews and physician case report programmes where secondary data is unavailable.
Payers and formulary committees across GCC increasingly reject Western RCT extrapolations. Local RWD demonstrating treatment patterns, outcomes, and costs in Arab patient populations is now a differentiated access lever.
UAE and Saudi Arabia have structured EMR and national data platforms; Egypt and smaller GCC markets require primary data generation. Study design must match the data infrastructure of each target country.
Ethics requirements, data access timelines, and analytical standards vary by country. Teams that align RWD study design to SFDA NG-REG-005 and NUPCO evidence expectations from the outset avoid costly redesigns downstream.
Real-world data (RWD) is any data collected outside a traditional randomised controlled trial (RCT) that relates to patient health status, treatment delivery, and outcomes in routine clinical practice. The FDA defines RWD as "data relating to patient health status and/or the delivery of health care routinely collected from a variety of sources." In practice, RWD encompasses six primary data categories relevant to pharmaceutical market research in the Middle East:
Real-world data is the raw input; real-world evidence (RWE) is the analytical output. RWD becomes RWE only when it has been processed through a rigorous study design — with pre-specified research questions, defined inclusion/exclusion criteria, appropriate statistical methods, and transparent reporting of limitations. This distinction matters because regulatory bodies including the SFDA (in its Non-Interventional Study Guidelines, NG-REG-005), the European Medicines Agency, and the US FDA evaluate the quality of both the underlying data and the analytical approach before accepting RWE as a basis for regulatory or reimbursement decisions.
For pharmaceutical teams in the Middle East, the practical implication is that investing in high-quality RWD collection — through validated instruments, trained abstractors, and transparent data provenance documentation — is a prerequisite for generating RWE that will withstand payer and regulatory scrutiny. A physician survey of 50 cardiologists is RWD; a pre-specified cross-sectional study with validated sampling frame, non-response bias analysis, and hypothesis-driven analysis is RWE.
The UAE has the most mature digital health data infrastructure in the Middle East. The Dubai Health Authority's Salama system, introduced as a mandatory EMR platform for all DHA-licensed healthcare facilities in Dubai from 2013, covers approximately 3,500 healthcare providers and generates structured encounter data, prescription records, and diagnostic results for Dubai's resident population. Access for pharmaceutical research requires a DHA Research Ethics Committee approval and a formal data-sharing agreement with the DHA Health Information and Smart Health department. The Abu Dhabi Department of Health (DOH) operates the Al Emissary platform, which integrates EMR data from SEHA (Abu Dhabi Health Services Company) facilities and private providers under the Thiqa and Daman insurance schemes. The DHA Health Economics Department increasingly requests cost-effectiveness modelling supported by local RWD when evaluating high-cost specialty drugs for reimbursement. Timelines from ethics submission to data access typically run 6–10 weeks within Dubai.
Saudi Arabia's National Health Information Centre (NHIC), established as part of the MOH's e-Health transformation in 2016, represents the region's most ambitious health data aggregation initiative. The NHIC collects data from approximately 2,800 primary health care centres, 290 hospitals, and 100 specialised centres in the MOH network. Its interoperability programme has progressively linked hospital information systems to a centralised data warehouse. The MOH Statistical Yearbook, published annually, provides aggregate epidemiological data on outpatient visits, inpatient admissions, leading diagnoses, and procedure volumes — freely available and useful for burden of disease estimates and budget impact model population sizing. For pharmaceutical companies, the NHIC represents access to real patient-level data but requires a Saudi IRB-approved protocol, a data use agreement specifying anonymisation standards, and evidence of scientific merit. The SFDA's NCEHTA, which operates within the SFDA regulatory framework, references NHIC data standards in its HTA guidance and increasingly expects local data inputs in economic models.
Egypt presents a materially different data environment. EHR penetration across Egypt's 900+ public hospitals and approximately 6,000 private clinics remains low; the majority of patient encounters are documented on paper. The Egyptian Ministry of Health and Population (MOHP) has launched digital health initiatives under the Universal Health Insurance Authority (UHIA), which became operational in Port Said as a pilot in 2019 and is expanding nationally, but claims data from the UHIA system is not yet accessible for pharmaceutical research. The most significant Egyptian RWD asset is the National Hepatitis C Elimination Programme (2018–2020), which enrolled approximately 4.8 million patients through mass screening and treated over 2 million patients with direct-acting antivirals — generating one of the largest single-disease RWD datasets in the world. This programme produced published RWE on treatment completion rates, SVR outcomes, and adverse event profiles in the Egyptian population. For pharmaceutical companies conducting research in Egypt, primary data generation via chart review, physician CRF programmes, or prospective registry enrolment through university hospital sites remains the standard approach. CAPMAS (Central Agency for Public Mobilisation and Statistics) health data and MOHP aggregate statistics provide population denominators.
Kuwait's Ministry of Health operates a hospital information system across its 10 MOH hospitals but institutional EMR data is not routinely available for external pharmaceutical research. Kuwait Cancer Control Centre maintains disease-specific registry data. Qatar's Hamad Medical Corporation (HMC), which operates the national public healthcare system, maintains a unified EMR across its hospital network in Doha and supports an active clinical research programme; HMC-affiliated researchers can facilitate data access under collaborative research agreements. Bahrain's Ministry of Health and Oman's MOH have smaller healthcare networks with functional EMRs but no formal pharmaceutical data access frameworks. In these markets, physician CRF programmes and retrospective chart reviews through principal investigators at major hospitals remain the practical RWD generation pathway.
Across most Middle East markets, the absence of accessible secondary databases means that pharmaceutical teams must generate primary RWD. BioNixus applies four structured approaches:
Trained data abstractors extract pre-specified variables from paper or electronic patient records under ethics committee approval and site data access agreements. A standard oncology or chronic disease chart review covering 100 patients across two to three hospital sites will capture diagnosis date, treatment history, dose modifications, laboratory results, hospitalisation events, and outcome data. BioNixus-designed chart review tools include field-level validation rules, inter-rater reliability checks, and a monitoring plan aligned to ICH E6(R2). Cost benchmark: $15,000–$30,000 for 100 patients across 2–3 sites in KSA or UAE, depending on record complexity and number of variables extracted. Timeline: 14–20 weeks from ethics approval to clean dataset.
Structured physician CRF programmes enrol treating specialists to complete consented, anonymised data forms for consecutive patients meeting inclusion criteria. This approach is particularly effective for capturing real-world prescribing decisions, treatment modifications, and clinical outcomes in therapeutic areas where disease registry data is absent. A 200-patient physician CRF programme across Saudi Arabia, UAE, and Egypt with a 6-month follow-up period costs $25,000–$50,000. The output dataset can be analysed for treatment pattern mapping, adherence rates, and comparative effectiveness between therapeutic options — providing RWE for formulary dossiers and payer negotiations.
Direct patient interviews using validated PRO instruments generate self-reported health status, quality of life, and patient experience data unavailable in medical records. Arabic-language validated tools — including the EQ-5D-5L (Arabic UAE and Saudi versions), FACIT Fatigue Scale (Arabic), and SF-12 (Arabic) — enable generation of quality-of-life utility values for use in economic models, providing locally derived inputs that replace transferability assumptions from Western studies.
In markets where hospital pharmacy systems are structured, BioNixus can facilitate extraction of anonymised dispensing records — including drug, dose, fill date, and refill history — to generate longitudinal adherence and persistence data. This is most feasible in UAE hospital pharmacies operating on Salama-connected systems and in Saudi Arabia's NUPCO-procurement facilities.
RWD generated in the Middle East healthcare environment serves multiple strategic applications for pharmaceutical market access and HEOR teams:
The SFDA's Non-Interventional Study Guidelines (NG-REG-005) govern the design, conduct, and reporting of observational and RWD studies in Saudi Arabia. Companies conducting non-interventional studies in KSA must notify the SFDA, submit an ethics-approved protocol, and follow good pharmacoepidemiology practice standards. RWE generated under NG-REG-005 compliant protocols is accepted in support of variation applications, pharmacovigilance submissions, and label updates. The NCEHTA, which operates as part of the SFDA, explicitly references real-world evidence in its HTA reference case methodology — allowing sponsors to use local RWD in comparative effectiveness and cost-effectiveness arguments when RCT data does not reflect the Saudi clinical context.
The EMA's framework for RWD/RWE — elaborated through its Real World Evidence Task Force and the DARWIN EU platform — provides methodological standards that GCC teams can reference as international benchmarks. The FDA's 2021 Real World Evidence Program guidance and the Advancing Real-World Evidence Program set the global standard for using RWE in regulatory decision-making, and GCC regulators are increasingly aware of and aligned with these frameworks. Pharmaceutical teams generating RWE for the Middle East are advised to design studies that meet FDA/EMA methodological standards even if the immediate submission is to a regional body, as this positions the evidence package for global use.
NUPCO (National Unified Procurement Company) manages centralised drug procurement for Saudi Arabia's MOH sector, covering approximately 24% of total pharmaceutical spend in the Kingdom. Over the past three years, NUPCO's formulary committee has substantially increased its requests for local real-world data in the evaluation of specialty medicines. Specifically, NUPCO requests evidence of current treatment patterns in the KSA MOH patient population, local burden of disease data, and real-world outcomes data where available. Submissions lacking local data inputs are at increasing risk of rejected listings or deep pricing concessions as the condition of acceptance.
In Dubai, the DHA Health Economics Department evaluates high-cost medicines under the Essential Medicine List review process and increasingly requires cost-effectiveness modelling supported by locally relevant data inputs — particularly local utility values and unit costs — rather than direct transfer of published Western models. This creates a clear mandate for pharmaceutical teams to generate Gulf-specific RWD to anchor economic models to local clinical and cost contexts. See BioNixus capabilities in budget impact modelling for Saudi Arabia and HEOR consulting in Saudi Arabia for how RWD integrates into these economic analyses.
BioNixus designs and executes real-world data programmes with a decision-first orientation: every data element collected is tied to a specific evidence gap that needs to be addressed for a payer, regulatory, or commercial decision. Our Middle East RWD capability spans the full study lifecycle:
Related BioNixus services: real world evidence GCC, patient journey research GCC, UAE market access research.
Chart review (100 patients)
$15,000–$30,000
14–20 weeks from ethics approval to clean dataset across 2–3 hospital sites.
Physician CRF programme (200 patients)
$25,000–$50,000
16–28 weeks including site setup, 12–16 weeks data collection, analysis and report.
Markets covered
KSA, UAE, EGY +
Active site networks across Saudi Arabia, UAE, Egypt, Kuwait, Qatar, and Oman.
Real-world data (RWD) refers to the raw data collected outside of traditional controlled clinical trials — drawn from electronic health records, claims databases, patient registries, pharmacy dispensing systems, patient-reported outcome instruments, and wearable or sensor devices. Real-world evidence (RWE) is the clinical and scientific evidence generated through rigorous analysis of that raw data. In practice, RWD is the input and RWE is the output. A claim that a treatment reduces hospitalisation by 28% in a Middle East diabetic population is RWE; the underlying hospital discharge records, prescription data, and HbA1c lab values are the RWD. Regulatory bodies including the SFDA, EMA, and FDA have published distinct frameworks for the governance of each stage, and pharmaceutical teams must satisfy both layers — data provenance and analytical rigour — to produce RWE that can support formulary, pricing, or regulatory submissions.
The GCC is heterogeneous in its data infrastructure. Saudi Arabia has the most developed national framework: the National Health Information Centre (NHIC) aggregates MOH-facility claims, hospital discharge data, and laboratory results for approximately 25 million citizens and residents, with selective access for approved research partners. The UAE operates two complementary systems — the Dubai Health Authority's Salama EMR platform (mandatory for all DHA-licensed Dubai facilities since 2013) and the Abu Dhabi DOH Al Emissary dataset; both can generate prescription-level dispensing data and outpatient encounter records under data-sharing agreements. Kuwait's Ministry of Health hospital information system covers the public sector, though interoperability with private facilities is limited. Qatar's Hamad Medical Corporation maintains a unified EMR across its hospital network. In Oman and Bahrain, institutional EMRs are present but national aggregation is nascent. Across all six countries, private insurance claims data from major insurers (Tawuniya, Bupa Arabia, Daman, AXA Gulf) represent a growing secondary data source. For specialty drugs, NUPCO dispensing records in Saudi Arabia provide longitudinal prescription fills for MOH-sector patients.
When secondary RWD is inaccessible — which remains the reality for most specialty pharmaceutical studies in Egypt and several GCC markets — BioNixus generates primary RWD through three structured approaches. First, retrospective chart review: trained abstractors extract pre-specified data elements from paper or digital hospital records under ethics committee approval; a chart review of 100 oncology patients in a teaching hospital typically takes 8–12 weeks and costs $15,000–$30,000 depending on data complexity. Second, physician case report form (CRF) programmes: structured, consented data collection from 150–300 treating physicians documenting consecutive patient encounters; a 200-patient physician CRF programme across three GCC countries costs $25,000–$50,000 and runs for 12–20 weeks. Third, patient-reported outcome (PRO) surveys and registry enrolment: patients are prospectively enrolled through outpatient clinics or patient support programmes, completing validated instruments such as EQ-5D-5L, SF-12, or disease-specific PRO tools translated and culturally adapted for Arabic-speaking populations. Each approach requires a site-specific ethics submission, data processing agreements, and a monitoring plan to meet SFDA NG-REG-005 and ICH E6(R2) good clinical practice standards for observational studies.
Yes, and it is increasingly expected. NUPCO (National Unified Procurement Company) manages drug procurement for the Saudi MOH sector — approximately 24% of the total KSA pharmaceutical market by volume — and its formulary committee has over the past three years placed growing weight on local real-world outcomes data. Specifically, committees request treatment utilisation analysis showing current prescribing patterns under existing formulary options, burden of disease data quantifying unmet need in the MOH patient population, and comparative effectiveness data from non-interventional studies or chart reviews. Budget impact models submitted to NUPCO should ideally incorporate local RWD-derived market share and treatment duration assumptions rather than relying solely on global RCT efficacy extrapolations. BioNixus structures RWD programmes with the NUPCO submission pathway in mind: data collection instruments are pre-aligned to the evidence requirements, and outputs are formatted as dossier-ready modules that can be inserted directly into the technical assessment package.
The National Health Information Centre (NHIC) is Saudi Arabia's central health data authority, established under the Ministry of Health and operational since 2016. Its core mandate is to aggregate, standardise, and govern health data across all MOH-affiliated facilities — covering primary health care centres, general hospitals, and specialised hospitals — and to make this data available for approved health research and policy purposes. For pharmaceutical companies, the NHIC represents the closest analogue to national-level secondary RWD in the GCC. Approved research partners can apply for access to anonymised patient-level datasets covering inpatient discharge records, outpatient encounter data, laboratory test results, and primary care consultations. The NHIC also publishes the MOH Statistical Yearbook, which contains aggregate epidemiological data on disease incidence, hospital bed utilisation, and procedure volumes — useful for burden of disease calculations and model population sizing. Gaining NHIC data access requires a Saudi IRB-approved protocol, a data use agreement, and alignment with the NHIC research priority areas. Typical approval timelines run 3–6 months. BioNixus supports the full submission process and can advise on study design to maximise the probability of access approval.
Timeline varies considerably by country, study design, and data source. A retrospective chart review in a single UAE or Saudi hospital with an existing ethics committee process runs approximately 14–20 weeks from protocol finalisation to clean dataset delivery: 2–4 weeks for ethics submission and approval (DHA research ethics or MOH IRB), 1–2 weeks for site contracting, 6–10 weeks for data abstraction, and 2–4 weeks for data cleaning and analysis. Multi-country chart reviews spanning KSA, UAE, and Egypt add 4–8 weeks to accommodate parallel ethics submissions and site-level variation in record completeness. Physician CRF programmes — which involve prospective data collection from consented treating physicians — typically run 16–28 weeks including site setup, 12–16 weeks of data collection, and 4–6 weeks of analysis. NHIC secondary data studies have the longest lead time due to institutional access approval, but analysis itself is faster once data are secured. Egypt adds a specific complexity: lower EMR penetration means chart reviews often involve paper record abstraction by on-site teams, which increases cost and timeline by 20–30% relative to UAE or KSA equivalent studies.